B · Normal
[ST Renfu: Subsidiary Brivaracetam Tablets Marketing Application Accepted] On November 12, ST Renfu (600079.SH) announced that the company's controlled subsidiary Yichang Renfu recently received the "Acceptance Notice" for the drug registration and marketing license application for Brivaracetam Tablets approved and issued by the State Food and Drug Administration. This drug is a Class 3 chemical drug, and its indications are monotherapy and add-on treatment for partial seizures in patients with epilepsy aged 16 years and above. Up to now, Yichang Renfu has invested approximately 37 million yuan in R&D in this project.
A-share announcement express 🕐 2026-11-12 16:25
#Chemical #A-share announcement express
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

[Hengrui Pharmaceuticals: Subsidiary’s Class 1 new drug rifucibamab injection ha 11-12 16:43 [Bori Pharmaceuticals: Controlling shareholder, actual controller and persons ac 11-12 16:39 [Shenghui Technology: Signed a 120 million yuan new energy power swap station co 11-12 16:33 [Qianyuan Electric Power: Recently, Guoxin Industrial Capital has increased its 11-12 16:27 [Yonggui Electric: Its holding subsidiary won the bid for a 21.45 million yuan p 11-12 16:14 [Guangshengtang: Hepatitis B triple all-oral regimen completes phase II clinical 11-12 16:04

Comments

0/500
Captcha (click to refresh)
No comments yet